July 18, 2008

From the News Wire: Lantus vs NPH: Safer not better control

Long-Acting Insulins in Type 1 Diabetes Safer Than Traditional Agents

For type 1 diabetes, long-acting insulins such as glargine (Lantus) reduce severe hypoglycemic episodes but don't offer clinically significant improved glycemic control, according to a meta-analysis.

1 comment:

Scott said...

Interestingly, the standard of using NPH as the control misses the fact that the Lente series (consisting of Semilente, Lente and Ultralente) was widely-regarded as superior in terms of phamcokinetics/pharmacodynamics (PK/PD), yet because it is more difficult to make, it was among the first range of older products to be removed from the market. However, a better review might compare Lantus/Levemir to Lente products (still sold in a number of other countries) to see if there is any difference in the incidence of hypoglycemia -- I would bet that analogues would not show much of statistical difference reducing severe hypoglycemic episodes if they compared it to Lente.

See http://www.hbns.org/getDocument.cfm?documentID=1741 for more.